Adalimumab biosimilar (Alphamab)

阿达木单抗生物类似药 (Alphamab)

Report date: 2022/09/02 20:00:31

Base Information

Drug NameAdalimumab biosimilar (Alphamab)
Drug Alias Name阿达木单抗生物仿制药 (Alphamab)KN-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesSuzhou Alphamab Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlphamab Jilin Co Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeL04AB04
Related LinksN/A